市场见解

Starpharma (ASX:SPL) share price climbs 3% on back of Vietnam launch

What’s happening with the biopharmaceutical company?
The post Starpharma (ASX:SPL) share price climbs 3% on back of Vietnam launch appeared first on The Motley Fool Australia. –

The Starpharma Holdings Limited (ASX: SPL) share price edged higher today following the launch of Viraleze in Vietnam this week.

Viraleze is an antiviral nasal spray that has been shown to deactivate a broad spectrum of respiratory/cold viruses in laboratory studies. This includes multiple variants of SARS-CoV-2 (COVID-19), influenza, RSV, SARS, and MERS (Middle East Respiratory Syndrome).

At the close of trading on Friday, shares in the dendrimer products developer were up 2.99% to $1.205. At one point, the share price hit an intraday high of $1.235 — up 5.5% on Starpharma’s previous close.

What did Starpharma announce?

In today’s release, Starpharma announced that Viraleze has been registered for sale in Vietnam.

Viraleze is being launched in the south-east Asian country this week, following the recently-signed initial supply contract. About 100,000 units will be supplied under distribution agreements with Australian-based Healthco, and Vietnam-based Truong Bao Land International Investment Company.

These arrangements are exclusive for retail, pharmacies, clinics, and hospitals in Vietnam. However, a portion of these orders will also be donated to hospitals and other healthcare organisations across the country.

Vietnam has a population of about 97 million. It is currently experiencing a significant Delta outbreak despite 50% of its population being fully vaccinated. According to the World Health Organisation (WHO), Covid-19 has taken 25,600 lives in Vietnam so far.

Starpharma CEO, Dr Jackie Fairley commented:

Starpharma is pleased to have achieved another registration for VIRALEZETM, and we are excited to see the product launched in Vietnam this week. This registration, the first in South East Asia, builds upon existing submissions as well as registrations already achieved in Europe, India and New Zealand, and we are expediting further regulatory submissions in multiple regions and countries.

Starpharma share price snapshot

At the start of 2021, Starpharma shares rocketed to an all-time high of $2.52 in mid-February. This followed a couple of positive market announcements.

First was the global expansion of AstraZeneca’s AZD0466 clinical development program, which is using Starpharma’s proprietary DEP technology, to develop a leukaemia treatment.

Starpharma also announced the signing of a research agreement with Merck & Co., Inc (MSD). Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer-based Antibody Drug Conjugates (ADCs) also using Starpharma’s DEP technology.

However, the sharp rise in the Starpharma share price didn’t last. It came crashing down in late February. Since then, the company’s shares have continued their downward trend and hit a 52-week low of $1 in November.

Starpharma is down by 7% in the past 12 months. It is 22% lower in 2021 alone.

The post Starpharma (ASX:SPL) share price climbs 3% on back of Vietnam launch appeared first on The Motley Fool Australia.

These 5 Cheap Shares Could Be Set For Huge Gains (FREE REPORT)

We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can find out the names of these stocks in the FREE stock report.

*Extreme Opportunities returns as of February 15th 2021

More reading

Why Bellevue Gold, South32, Starpharma, and Tuas shares are pushing higher

The Starpharma (ASX: SPL) share price surges on Vietnam launch

Starpharma (ASX:SPL) share price jumps 6% following AGM

Why is the Starpharma (ASX:SPL) share price trading at 52-week lows?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

随时随地,交易世界!

移动APP平台,拥有 12 个市场的 50,000 多种全球上市证券(全球市值超过 70%),直接在您的 Android 或 iOS 设备上即可操作。

与独有的交易理念和投资分析工具相结合,帮助您在我们 12 个全球市场中的几乎所有金融工具上找到可操作的见解,从而帮助您优化交易策略。

推荐给您的朋友

向您的朋友推荐Monex并赠予他们免费使用我们交易工具的机会

我们尊重您的隐私,只会向您的朋友发送一封邮件 

与您的朋友分享

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!